Prevention of cholesterol gallstone disease by FXR agonists in a mouse model

Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR

Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636

Targeting bile‐acid signalling for metabolic diseases

Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422

Bile acid signaling in metabolic disease and drug therapy

Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935

Gallstones

Lammert, F., Gurusamy, K., Ko, C. W., Miquel, J.-F., Méndez-Sánchez, N., Portincasa, P., van Erpecum, K. J., van Laarhoven, C. J., & Wang, D. Q.-H. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.24 · Cited by 822

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR

Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779

Cholesterol gallstone disease

Portincasa, P., Moschetta, A., & Palasciano, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69044-2 · Cited by 643

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639

LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism

Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615

Endocrine functions of bile acids

Houten, S. M., Watanabe, M., & Auwerx, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601049 · Cited by 580

Bile acid nuclear receptor FXR and digestive system diseases

Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477

Molecular physiology of bile acid signaling in health, disease, and aging

Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481

FXR, a multipurpose nuclear receptor

Lee, F. Y., Lee, H., Hubbert, M. L., Edwards, P. A., & Zhang, Y. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.002 · Cited by 344

Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations

Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286

New molecular insights into the mechanisms of cholestasis

Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 260

Functional Variants of the Central Bile Acid Sensor FXR Identified in Intrahepatic Cholestasis of Pregnancy

van Mil, S. W. C., Milona, A., Dixon, P. H., Mullenbach, R., Geenes, V. L., Chambers, J., Shevchuk, V., Moore, G. E., Lammert, F., Glantz, A. G., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.015 · Cited by 257

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090114 · Cited by 169

miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity

Allen, R. M., Marquart, T. J., Albert, C. J., Suchy, F. J., Wang, D. Q. ‐., Ananthanarayanan, M., Ford, D. A., & Baldán, Á. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201228 · Cited by 159

Nuclear receptors as therapeutic targets in cholestatic liver diseases

Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146

TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders

Tiwari, A., & Maiti, P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.005 · Cited by 122

Genome–microbiome interplay provides insight into the determinants of the human blood metabolome

Diener, C., Dai, C. L., Wilmanski, T., Baloni, P., Smith, B., Rappaport, N., Hood, L., Magis, A. T., & Gibbons, S. M. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00670-1 · Cited by 102

Hepatic Deletion of SIRT1 Decreases Hepatocyte Nuclear Factor 1 α/Farnesoid X Receptor Signaling and Induces Formation of Cholesterol Gallstones in Mice

Purushotham, A., Xu, Q., Lu, J., Foley, J. F., Yan, X., Kim, D.-H., Kemper, J. K., & Li, X. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05988-11 · Cited by 87

Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts

Petruzzelli, M., Vacca, M., Moschetta, A., Cinzia Sasso, R., Palasciano, G., van Erpecum, K. J., & Portincasa, P. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.01.015 · Cited by 46